Watson Pharma.


Reports last week suggested that drug maker Watson Pharmaceuticals Inc. is in talks to buy European counterpart Actavis. Citing unidentified sources, Reuters said the Parsippany, N.J., company could pay up to $7.3 billion for privately held Actavis. Both companies declined to comment. In May, Watson bought generics maker Specifar Pharmaceuticals of Greece in a deal valued at $563.1 million.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of